Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)455.20m
- Net income in EUR28.56m
- Incorporated1967
- Employees2.77k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttp://www.boiron.fr/
More ▼
Mergers & acquisitions
| Acquired company | BOI:PAR since announced | Transaction value |
|---|---|---|
| Abbi Sas | 10.48% | 1.98m |
Data delayed at least 15 minutes, as of May 19 2022 12:41 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharming Group N.V. | 190.65m | 15.34m | 482.07m | 321.00 | 33.98 | 2.61 | 14.12 | 2.53 | 0.0219 | 0.0219 | 0.2645 | 0.2851 | 0.4876 | 0.8724 | 6.04 | 593,936.60 | 3.92 | 2.73 | 4.62 | 3.87 | 89.37 | 87.36 | 8.04 | 4.39 | 4.75 | -- | 0.4561 | -- | -6.27 | 62.49 | -57.62 | -- | 66.17 | -- |
| Oxford BioMedica plc | 168.35m | 22.41m | 569.65m | 815.00 | 22.41 | 2.31 | 15.36 | 3.38 | 0.2245 | 0.2245 | 1.67 | 2.17 | 0.6781 | 7.32 | 3.58 | 175,211.00 | 9.03 | -0.756 | 11.34 | -0.9976 | 57.87 | 55.20 | 13.31 | -1.20 | 4.63 | 20.40 | 0.0475 | -- | 62.77 | 38.74 | 404.42 | -- | 7.94 | -- |
| Pharmanutra SpA | 68.11m | 13.77m | 584.73m | 64.00 | 42.38 | 12.97 | 39.18 | 8.58 | 1.43 | 1.43 | 7.05 | 4.66 | 1.11 | 0.9637 | 4.29 | -- | 22.38 | 23.06 | 28.94 | 32.33 | 96.63 | 95.39 | 20.22 | 19.37 | 3.14 | -- | 0.1235 | 50.80 | 20.66 | 15.75 | -2.14 | 29.03 | 18.07 | -- |
| Puretech Health PLC | 16.64m | -57.96m | 590.90m | 95.00 | -- | 1.04 | -- | 35.50 | -0.1721 | -0.1721 | 0.0493 | 1.67 | 0.018 | -- | 6.07 | 148,601.50 | -6.48 | 4.86 | -8.07 | 6.24 | -- | -- | -360.65 | 260.53 | -- | -- | 0.0818 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Ergomed PLC | 139.80m | 14.94m | 608.32m | 1.01k | 41.59 | 7.63 | 29.12 | 4.35 | 0.2505 | 0.2505 | 2.34 | 1.36 | 1.20 | -- | 4.41 | -- | 12.78 | 4.27 | 19.60 | 6.13 | 40.78 | 41.18 | 10.69 | 3.85 | -- | 53.75 | 0.0383 | -- | 37.26 | 24.76 | 30.90 | -- | -2.38 | -- |
| MorphoSys AG | 173.89m | -595.50m | 614.46m | 652.00 | -- | 4.32 | -- | 3.53 | -17.46 | -17.46 | 5.05 | 4.15 | 0.0847 | 2.04 | 1.98 | 237,552.90 | -29.00 | -13.97 | -32.49 | -15.73 | 79.85 | -- | -342.46 | -89.38 | 4.15 | -3.06 | 0.6984 | -- | -45.19 | 29.28 | -625.55 | -- | 55.11 | -- |
| Formycon AG | 38.44m | -14.71m | 693.72m | 159.00 | -- | 11.80 | -- | 18.05 | -1.30 | -1.30 | 3.34 | 5.32 | 0.6244 | 56.09 | 5.00 | 293,434.00 | -24.03 | -3.37 | -27.89 | -3.73 | 5.18 | 32.68 | -38.48 | -4.22 | 3.65 | -66.20 | 0.00 | -- | 2.12 | 15.09 | -158.39 | -- | -0.6022 | -- |
| Boiron SA | 455.20m | 28.56m | 707.96m | 2.77k | 24.76 | 1.33 | 16.73 | 1.56 | 1.63 | 1.63 | 25.99 | 30.36 | 0.5864 | 1.50 | 4.89 | 164,391.80 | 3.68 | 5.96 | 4.69 | 7.50 | 71.97 | 76.84 | 6.27 | 8.41 | 2.32 | -- | 0.0232 | 46.86 | -11.37 | -5.82 | 8.95 | -18.15 | -10.06 | -9.90 |
| Alliance Pharma plc | 192.41m | 8.63m | 709.75m | 255.00 | 82.91 | 2.13 | 34.55 | 3.69 | 0.0135 | 0.0135 | 0.3024 | 0.5249 | 0.3224 | 2.44 | 6.74 | 640,027.40 | 1.45 | 4.23 | 1.55 | 4.82 | 67.06 | 63.24 | 4.48 | 13.50 | 1.48 | 8.11 | 0.2963 | 39.33 | 25.74 | 10.85 | -8.82 | -16.56 | 31.70 | 6.92 |
| Surgical Science Sweden AB | 34.84m | 8.19m | 730.49m | 211.00 | 66.95 | 2.15 | 64.22 | 20.97 | 2.26 | 2.26 | 9.59 | 70.57 | 0.1648 | 1.61 | 5.68 | -- | 3.88 | 3.41 | 4.12 | 3.67 | 72.51 | 78.80 | 23.52 | 15.42 | 2.17 | -- | 0.0429 | 0.00 | 249.98 | 47.90 | 452.66 | 92.43 | 4.25 | -- |
| Northern Data AG | 16.38m | -84.26m | 828.78m | 157.00 | -- | 2.89 | -- | 50.61 | -7.25 | -7.25 | 1.41 | 12.06 | -- | -- | -- | 104,314.40 | -- | -35.75 | -- | -72.57 | 37.20 | -6.61 | -514.48 | -343.85 | 0.301 | -0.5252 | 0.2519 | -- | 61.18 | 577.19 | -861.89 | -- | -- | -- |
| Nykode Therapeutics AS | 31.98m | -8.86m | 829.89m | 102.00 | -- | 4.54 | -- | 25.95 | -0.3812 | -0.3812 | 1.18 | 6.54 | 0.1371 | -- | 1.60 | 3,249,726.00 | -3.80 | 25.30 | -4.17 | 27.55 | -- | -- | -27.72 | 46.19 | -- | -31.51 | 0.0356 | -- | -84.20 | 311.05 | -106.29 | -- | 157.24 | -- |
| Cosmo Pharmaceuticals NV | 65.76m | 21.90m | 868.63m | 290.00 | 48.37 | 1.62 | 27.45 | 13.21 | 1.06 | 1.06 | 4.02 | 31.60 | 0.0929 | 3.50 | 2.53 | 234,486.00 | 3.09 | -2.09 | 3.21 | -2.16 | 49.32 | 59.64 | 33.31 | -19.05 | 12.37 | -- | 0.2489 | -- | 6.77 | -0.7776 | 374.29 | 2.30 | -14.33 | -- |
| Eckert&Ziegler Strahlen und Mdzntchnk AG | 186.17m | 27.33m | 882.87m | 930.00 | 31.72 | 4.43 | 23.80 | 4.74 | 1.31 | 1.31 | 8.95 | 9.41 | 0.5561 | 2.43 | 5.25 | 214,974.60 | 8.22 | 8.38 | 9.82 | 10.13 | 50.18 | 47.84 | 14.79 | 12.77 | 2.39 | -- | 0.1177 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Camurus AB | 66.00m | -6.58m | 889.42m | 149.00 | -- | 10.97 | -- | 13.48 | -1.27 | -1.27 | 12.73 | 15.56 | 0.6551 | 0.8601 | 5.81 | 4,695,635.00 | -6.53 | -27.66 | -8.06 | -33.82 | 86.21 | 86.73 | -9.98 | -84.90 | 2.64 | -66.37 | 0.0273 | -- | 78.74 | 39.49 | 45.93 | -- | 1.59 | -- |
| BioGaia AB | 82.34m | 21.10m | 929.46m | 189.00 | 45.73 | 5.19 | 39.94 | 11.29 | 11.00 | 11.00 | 42.94 | 96.88 | 0.4152 | -- | -- | 5,191,557.00 | 10.64 | 18.70 | 11.38 | 21.27 | 73.81 | 74.18 | 25.62 | 26.20 | -- | -- | 0.00 | 75.30 | 5.09 | 7.99 | 9.20 | 4.22 | 38.51 | -0.6484 |
Data as of May 19 2022. Currency figures normalised to Boiron SA's reporting currency: Euro EUR
12.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Natixis Investment Managers International SAas of 31 Dec 2021 | 1.01m | 5.78% |
| Financi�re de l'�chiquier SAas of 31 Dec 2020 | 445.80k | 2.54% |
| Sycomore Asset Management SAas of 30 Sep 2021 | 199.93k | 1.14% |
| BlackRock Fund Advisorsas of 04 May 2022 | 105.77k | 0.60% |
| Dimensional Fund Advisors LPas of 05 May 2022 | 93.29k | 0.53% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 83.48k | 0.48% |
| The Vanguard Group, Inc.as of 05 May 2022 | 78.62k | 0.45% |
| SMA Gestion SAas of 30 Jun 2020 | 75.56k | 0.43% |
| Tocqueville Finance SAas of 31 Mar 2022 | 29.15k | 0.17% |
| Fidecum AGas of 31 Jan 2022 | 29.00k | 0.17% |
More ▼
Data from 30 Jun 2020 - 29 Apr 2022Source: FactSet Research Systems Inc.
